
In-Vitro Toxicology/ Toxicity Testing Market (2019-2025)
The global In Vitro Toxicology/Toxicity Testing Market was valued at USD 14.72 billion in 2025. This market is expected to reach USD 42.50 billion by 2036 from an estimated USD 16.20 billion in 2026, registering a CAGR of 10.1% during the forecast period (2026-2036).
- Published
- Nov 2026
- Pages
- 189
- Format
- PDF + Excel
- Report ID
- MRHC - 104348
- Base year
- 2025
- 2025 · BASELINE
- $14.72B
- 2036
- $42.50B
- CAGR 2026–2036
- 10.1%
2025 baseline · 2026–2036 forecast at 10.1% CAGR · hover a bar for the value
Key highlights
By product and service, the services segment is expected to account for the largest share in 2026, while software is projected to register the highest CAGR during the forecast period.
By technology, the cell culture technologies segment is expected to hold the largest share in 2026, while OMICS technologies are projected to grow fastest.
By method, the cell-based assays segment is expected to account for the largest share in 2026, while in-silico methods are projected to register the highest CAGR.
By end-point, the cytotoxicity segment is expected to hold the largest share in 2026, while organ toxicity is projected to grow fastest.
By end-user, the pharmaceutical and biotechnology industries segment is expected to account for the largest share in 2026 and is also projected to grow fastest.
By geography, North America is expected to hold the largest share in 2026, while Asia-Pacific is projected to register the highest CAGR during the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Forecast Period | 2026-2036 |
| Market Size (2025) | USD 14.72 billion |
| Estimated Market Size (2026) | USD 16.20 billion |
| Forecast Market Size (2036) | USD 42.50 billion |
| CAGR (2026-2036) | 10.1% |
| Format | PDF, Excel & Cloud Portal · 189 pages |
| Units | Value (USD million/billion) |
| Segments Covered | Product & Service, Technology, Method, End-point, End-user, and Geography |
| Geographies Covered | North America (U.S., Canada), Europe (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa |
| Scope Inclusions | Equipment, assay kits, consumables, software and services for in vitro toxicology and toxicity testing across cell culture, high-throughput screening and OMICS technologies, using cell-based assays, biochemical assays, in-silico and ex-vivo methods, applied to ADME, skin irritation, corrosion, sensitization, genotoxicity, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity and other toxicity end-points, for the pharmaceutical and biotechnology, cosmetics, food and chemical industries |
| Scope Exclusions | In vivo and animal-based toxicology studies, animal breeding and supply, clinical trial services, in vitro diagnostic products for patient testing, analytical and bioanalytical services unrelated to toxicity assessment, regulatory consulting sold without testing or modelling, and distribution and logistics services |
| Key Companies | Charles River Laboratories International, Inc., Labcorp Holdings Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Eurofins Scientific SE, SGS SA, Bio-Rad Laboratories, Inc., QIAGEN N.V., Revvity, Inc., Agilent Technologies, Inc., Sartorius AG, Corning Incorporated, Promega Corporation, Lonza Group AG, Inotiv, Inc., WuXi AppTec Co., Ltd., Certara, Inc., and Simulations Plus, Inc. |
Report overview
Market value is measured in USD million/billion. Segments covered: product & service, technology, method, end-point, end-user. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is mainly driven by a mutual acceptance of data arrangement under which a test performed to an adopted test guideline must be accepted by every adhering country rather than repeated in each of them, by a cosmetics marketing ban that has applied to repeated dose toxicity, reproductive toxicity and toxicokinetics since 11 March 2013 regardless of whether alternative methods are available, by a nonclinical requirement that admits in vitro studies into an investigational new drug application alongside animal studies, by the number of candidate molecules entering safety assessment as pharmaceutical and biotechnology pipelines widen, and by organ and microphysiological models being built for the endpoints where no validated in vitro method yet exists. Regulatory acceptance rather than scientific capability determines what can be sold in this market, so demand follows guideline adoption more closely than it follows laboratory technique.
However, factors such as the absence of adopted test guidelines for systemic, repeated dose and reproductive endpoints which leaves those tests to be justified case by case, the requirement that a receiving authority accept the study while remaining free to interpret the results as it sees fit, the cost and duration of the validation work needed before a method can be proposed as a guideline, and the reluctance of sponsors to rely on a method a reviewer has not seen before in a submission that carries a clinical hold risk are expected to restrain the growth of this market to some extent. A method without a guideline competes against an animal study the reviewer already accepts, which is a commercial disadvantage no technical advantage overcomes quickly.
The Decision of the Council concerning the Mutual Acceptance of Data in the Assessment of Chemicals, OECD/LEGAL/0194, adopted on 12 May 1981, under which data generated in the testing of chemicals in one member country in accordance with the OECD Test Guidelines and the OECD Principles of Good Laboratory Practice shall be accepted in other member countries for purposes of assessment and for other uses relating to the protection of human health and the environment, with the receiving country obliged to accept the study while remaining free to interpret the results as it sees fit is what creates commercial value for an in vitro method. A test performed to an adopted test guideline under the principles of good laboratory practice satisfies every adhering country at once, so one study serves a global registration, while a method without a guideline has to be justified to each authority separately and may still be refused. Guideline adoption rather than scientific publication is therefore the event that converts a technique into a product, and the commercial history of this market is the history of which endpoints have obtained guidelines and which have not.
The endpoints that have obtained guidelines are the ones where in vitro testing is now routine, and they are concentrated in local and genetic effects. Skin irritation, skin corrosion, serious eye damage and eye irritation, skin sensitisation, phototoxicity and in vitro genotoxicity are served by validated reconstructed tissue, cell line and biochemical methods that regulators accept without further justification. Systemic endpoints are not, and repeated dose toxicity, reproductive and developmental toxicity and carcinogenicity continue to rest on animal studies because no in vitro method has been validated to replace them. That division explains the share structure of the endpoint dimension far better than any measure of market demand.
The animal testing provisions of Regulation (EC) No 1223/2009, under which testing of finished cosmetic products on animals has been prohibited since 11 September 2004 and testing of ingredients and combinations of ingredients since 11 March 2009, while the marketing ban covering most human health effects took effect on 11 March 2009 and the marketing ban covering repeated dose toxicity, reproductive toxicity and toxicokinetics took effect on 11 March 2013 regardless of whether non-animal alternative methods are available created the one case in which demand ran ahead of method availability. The marketing ban took effect for repeated dose toxicity, reproductive toxicity and toxicokinetics on a fixed date whether or not alternatives existed, which left the cosmetics industry obliged to establish ingredient safety for exactly those endpoints without the animal studies the rest of industry uses and without validated in vitro replacements. The response has been read-across, exposure-based waiving and next generation risk assessment built from in vitro and in-silico data, and cosmetics has consequently been the sector that funded method development rather than merely purchased it.
The nonclinical requirement at 21 CFR 312.23(a)(8), under which the pharmacology and toxicology section of an investigational new drug application must contain adequate information about pharmacological and toxicological studies of the drug involving laboratory animals or in vitro, and at 21 CFR 312.23(a)(8)(ii)(a), which requires an integrated summary of the toxicological effects of the drug in animals and in vitro and includes any in vitro studies intended to evaluate drug toxicity settles the question of admissibility in pharmaceutical development. In vitro studies are not an alternative a sponsor must argue for in an investigational new drug application, they are named in the regulation alongside animal studies and must be summarised in the integrated toxicology summary. Adoption in pharmaceutical safety assessment is therefore a question of reviewer confidence and of whether a method answers the question a reviewer is asking, rather than a question of permission, which is why pharmaceutical and biotechnology companies are the largest and the fastest-growing end user in this market.
Services account for the largest share of the product and service dimension because safety assessment is commissioned rather than performed in-house by most sponsors. A pharmaceutical company running a candidate through genetic toxicology, in vitro ADME and local tolerance testing buys those studies from a contract laboratory holding good laboratory practice status and the specific guideline experience, and a cosmetics or chemical company does the same. The provider carries the regulatory status, the validated method and the audit history, and the sponsor buys the report rather than the capability, which concentrates spending on a smaller number of laboratories than the number of companies generating the demand.
Assay kits and consumables carry the product value and are bought by both the service providers and the sponsors that test internally. A reconstructed human epidermis model, a cell line validated for a specific guideline, a metabolic competence system or a multiplexed cytotoxicity panel is consumed with every test performed, and the guideline frequently names the model or specifies characteristics only a small number of products meet. Equipment grows more slowly because an instrument is bought once while the plates, media and reagents it runs are consumed continuously, and the instrument placement nonetheless determines which consumables a laboratory buys for its service life.
Software is the fastest-growing offering because in-silico prediction and the data management around it have moved from supporting role to evidence in their own right. Quantitative structure activity models, physiologically based pharmacokinetic models, read-across tools and adverse outcome pathway frameworks are used to set testing strategy, to waive tests where exposure allows and to support a safety conclusion where no validated test exists, and they carry licence economics rather than consumable economics. The in-silico method segment grows fastest for the same reason, and the two overlap because the model and the software that runs it are generally bought together.
Organ toxicity is the fastest-growing endpoint and the one where the method gap is widest. Microphysiological systems, organ-on-chip platforms and three-dimensional tissue models are being built specifically for liver, cardiac, kidney, lung and neuronal toxicity, which are the endpoints that cause attrition in development and that current in vitro methods predict poorly, and investment is flowing there because the commercial prize is replacing a study that no in vitro method currently replaces. The absence of adopted guidelines for those endpoints is the reason the opportunity exists and the reason it converts slowly.
Market dynamics
15 factors across 5 forcesMutual acceptance of data that makes one guideline test serve every adhering country
the Decision of the Council concerning the Mutual Acceptance of Data in the Assessment of Chemicals, OECD/LEGAL/0194, adopted on 12 May 1981, under which data generated in the testing of chemicals in one member country in accordance with the OECD Test Guidelines and the OECD Principles of Good Laboratory Practice shall be accepted in other member countries for purposes of assessment and for other uses relating to the protection of human health and the environment, with the receiving country obliged to accept the study while remaining free to interpret the results as it sees fit means that a study performed once to an adopted guideline supports registration across the adhering countries rather than having to be repeated for each, which multiplies the value of a method the moment a guideline covers it and leaves a method without one competing study by study. A provider holding good laboratory practice status and guideline-compliant methods therefore sells into global registration programmes rather than national ones, and a sponsor choosing between a guideline method and a better unvalidated one chooses the guideline method because the data travels. Guideline adoption is consequently the single most consequential event in the commercial life of any in vitro toxicology method.
A cosmetics marketing ban applying regardless of alternative availability
the animal testing provisions of Regulation (EC) No 1223/2009, under which testing of finished cosmetic products on animals has been prohibited since 11 September 2004 and testing of ingredients and combinations of ingredients since 11 March 2009, while the marketing ban covering most human health effects took effect on 11 March 2009 and the marketing ban covering repeated dose toxicity, reproductive toxicity and toxicokinetics took effect on 11 March 2013 regardless of whether non-animal alternative methods are available obliges the cosmetics industry to establish ingredient safety for repeated dose toxicity, reproductive toxicity and toxicokinetics without animal studies and without validated in vitro replacements for those endpoints. The sector has responded by building next generation risk assessment from in vitro and in-silico data, by exposure-based waiving and by read-across from substances with existing data, and the spending that produces is directed at method development and at assay panels rather than at single guideline studies. Cosmetics demand therefore funds capability in this market rather than only consuming it.
A nonclinical requirement that admits in vitro studies into drug applications
the nonclinical requirement at 21 CFR 312.23(a)(8), under which the pharmacology and toxicology section of an investigational new drug application must contain adequate information about pharmacological and toxicological studies of the drug involving laboratory animals or in vitro, and at 21 CFR 312.23(a)(8)(ii)(a), which requires an integrated summary of the toxicological effects of the drug in animals and in vitro and includes any in vitro studies intended to evaluate drug toxicity removes permission as an obstacle in pharmaceutical safety assessment, since in vitro studies are named in the regulation alongside animal studies and must appear in the integrated toxicology summary. Sponsors therefore adopt in vitro methods where they answer the question faster, cheaper or with better human relevance than the animal study, and the constraint is reviewer confidence rather than regulatory acceptability. Pharmaceutical and biotechnology companies are the largest end user in this market for that reason, and their adoption rate rather than any change in the rules is what sets the growth of the largest segment.
Candidate volume entering safety assessment as pipelines widen
Every molecule entering development consumes a standard package of early safety work covering genetic toxicology, in vitro ADME, cytotoxicity, hERG and other cardiac liability screening and local tolerance, and the number of molecules reaching that stage has risen with the growth of biotechnology pipelines and with discovery platforms that generate more candidates per programme. Because the package is run per candidate rather than per approved product, demand in this market tracks the number of molecules entering development rather than the number reaching the market, which makes it far less exposed to late stage attrition than most parts of the pharmaceutical supply chain.
Table of contents
13 chapters · 169 sections · 189 pages · click to expandGeographic analysis
Asia-Pacific
Fastest growthContract research capacity for safety assessment is being built across China, India, South Korea and Japan at the same time as national authorities align with the adopted test guidelines and the good laboratory practice principles, and alignment is what makes work performed in the region usable in a global registration. Providers establishing guideline-compliant and good laboratory practice certified capacity in the region therefore serve both domestic sponsors and the global programmes that place work there, and the cost position supports pricing that western laboratories cannot match on routine guideline studies. Asia-Pacific is the fastest-growing region in this market for that reason. Cosmetics and chemical demand in the region is growing alongside the pharmaceutical demand, since national frameworks there have moved toward accepting non-animal data for ingredient assessment, so a provider establishing capacity serves three industries from one certified site. Local sponsors in the region also place routine guideline work domestically rather than exporting it, which is new demand rather than transferred demand. Asia-Pacific is projected to register the highest CAGR of 12.0% during the forecast period, valued at USD 3,499.2 million in 2026 and reaching USD 10,868.0 million by 2036. China combines the largest contract research capacity build in the region with national alignment to the adopted test guidelines and good laboratory practice principles, which is what makes work performed there usable in a global registration, and with a cosmetics regulatory framework that has moved toward accepting non-animal data. India carries substantial contract research and generic development demand, Japan operates a mature pharmaceutical development base with its own regulatory science capability, South Korea combines pharmaceutical and cosmetics industries that both generate demand, and Australia contributes academic and contract capability. Growth is faster than elsewhere because capacity build and regulatory alignment act together rather than separately. Asia-Pacific capacity and guideline adoption across the region Geographic Analysis
North America
Largest shareNorth America is expected to account for the largest share of this market in 2026, valued at USD 6,868.8 million, with the U.S. accounting for USD 6,285.0 million of that total. The regional position rests on the concentration of pharmaceutical and biotechnology development spending in the country, on a nonclinical regulation that names in vitro studies alongside animal studies in an investigational new drug application and requires them in the integrated toxicology summary, on the depth of contract safety assessment capacity holding good laboratory practice status, and on the density of platform developers building microphysiological and organ-on-chip systems. Canada contributes through contract research capacity and chemical substance assessment requirements of its own.
Europe
Europe follows, valued at USD 4,827.6 million in 2026 and projected to reach USD 12,295.7 million by 2036 at a CAGR of 9.8%, with demand across Germany, the United Kingdom, France, Italy, Spain, Switzerland and the Netherlands. The region carries the most demanding regulatory position in this market, because the cosmetics marketing ban has applied to repeated dose toxicity, reproductive toxicity and toxicokinetics since 11 March 2013 regardless of whether alternatives exist, and because chemical substance registration generates large data requirements that applicants must meet with as little animal testing as the rules permit. Germany holds the largest country share on chemical and pharmaceutical industry scale, Switzerland combines pharmaceutical development with contract testing capacity, the United Kingdom holds substantial method development and contract research capability, and the Netherlands carries both research institutes and regulatory science capacity.
Latin America
Latin America is valued at USD 615.6 million in 2026 and grows at 10.2% with Brazil and Mexico carrying most of the demand, and the Middle East & Africa accounts for USD 388.8 million at a CAGR of 10.4% from the smallest base.
Competitive landscape
Participants in this market fall into groups that sell to different budgets. Contract research organisations supply regulated safety assessment studies to good laboratory practice standard and compete on guideline coverage, audit history, capacity and turnaround rather than on method novelty, since a sponsor buying a guideline study wants it performed exactly as the guideline prescribes. Life science product companies supply the assay kits, consumables, cell and tissue models, instrumentation and screening systems that both the contract laboratories and the sponsors testing internally consume, and compete on guideline compatibility, lot-to-lot consistency and breadth. In-silico and modelling companies supply the software and the models behind it on licence terms, and platform developers supply microphysiological and three-dimensional systems into research budgets while validation proceeds.
Competitive position rests on guideline coverage, good laboratory practice status and model consistency rather than on technical performance alone, because a method a regulator has not accepted competes against an animal study the regulator already accepts. Some of the key players operating in the in vitro toxicology and toxicity testing market are Charles River Laboratories International, Inc., Labcorp Holdings Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Eurofins Scientific SE, SGS SA, Bio-Rad Laboratories, Inc., QIAGEN N.V., Revvity, Inc., Agilent Technologies, Inc., Sartorius AG, Corning Incorporated, Promega Corporation, Lonza Group AG, Inotiv, Inc., WuXi AppTec Co., Ltd., Certara, Inc., and Simulations Plus, Inc., among others. Growth strategies across the participant base centre on adding guideline coverage, on acquiring cell and tissue model capability, on building in-silico and data integration capacity, and on establishing good laboratory practice certified capacity in Asia-Pacific, and acquisitions have been directed at model and software capability rather than at laboratory capacity. Animal breeding and supply businesses without testing services are not participants in this market, nor are regulators and guideline bodies, academic laboratories performing no commercial testing, and clinical trial service providers, since none of these supply a test, a model or a prediction into the market as defined. Acquisitions across the participant base have been directed at cell and tissue model capability and at in-silico and data integration businesses rather than at laboratory capacity, because capacity is available and validated methods are not.
- Charles River Laboratories International, Inc.
- Labcorp Holdings Inc.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Eurofins Scientific SE
- SGS SA
- Bio-Rad Laboratories, Inc.
- QIAGEN N.V.
- Revvity, Inc.
- Agilent Technologies, Inc.
- Sartorius AG
- Corning Incorporated
- Promega Corporation
- Lonza Group AG
- Inotiv, Inc.
- WuXi AppTec Co., Ltd.
- Certara, Inc.
- Simulations Plus, Inc
Expert perspectives
Regulatory acceptance rather than scientific capability decides what can be sold in this market. Under the Decision of the Council concerning the Mutual Acceptance of Data, adopted on 12 May 1981, data generated to an adopted test guideline under the principles of good laboratory practice must be accepted in other member countries for purposes of assessment, so one study serves a global registration, while the receiving authority remains free to interpret the results as it sees fit and has no acceptance obligation at all for a method outside the guidelines. The endpoints with guidelines are therefore where in vitro testing is routine, and the systemic endpoints without them remain with animal studies. The binding constraint is therefore shifting from whether a method works toward whether a guideline covers it and a reviewer will rely on it.
Spending will move toward the methods that answer questions no guideline study currently answers and toward the software that frames them. Software will grow fastest among the product and service categories, on in-silico prediction moving from triage toward evidence and on licence economics. In-silico will grow fastest among the methods for the same reason. OMICS technologies will grow fastest among the technologies, on mechanistic readouts that an adverse outcome pathway argument requires. Organ toxicity will grow fastest among the endpoints, on liver, cardiac, kidney, lung and neuronal models built for the attrition endpoints current methods predict poorly. Pharmaceutical and biotechnology companies will remain both the largest and the fastest-growing end user, and Asia-Pacific will grow fastest among the regions as capacity build and guideline alignment act together.
For companies planning entry or expansion, guideline coverage is the asset and validation is the investment that creates it. A method named in or compliant with an adopted guideline sells into global registration programmes, and one without competes against an animal study the reviewer already accepts, so funding validation work is the route to the larger market even though it takes years and is rarely carried by a single developer alone. Model consistency should be treated as a reference material obligation rather than a reagent one, since a lot that performs differently forces customers to re-establish historical control data and is the fastest way to lose an installed position. In-silico and data integration capability deserves priority over additional laboratory capacity, because the conclusion a sponsor needs is increasingly assembled rather than measured.
Sponsors adopt new methods for internal decision making long before they rely on them in a submission, because an internal decision carries no regulatory risk while a submission can mean a clinical hold, so vendors reach research budgets years before they reach regulated study budgets. Validation timelines are the second qualification, since characterisation, interlaboratory reproduction, comparison against reference data and review take years and are partly publicly funded, which separates the party that funds validation from the party that captures the market. Reproducibility is the third, since cell source, passage, culture conditions, operator technique and model lot all move an in vitro result and the burden falls hardest on the three-dimensional and microphysiological systems carrying the most growth. Capacity location is the fourth, since guideline studies are migrating toward Asia-Pacific laboratories on cost while method development stays where the regulatory science sits, which separates where the revenue is earned from where the capability is built.
Overall, core demand through the forecast period comes from services supplying cell-based assays on cell culture technologies for cytotoxicity and genotoxicity endpoints to pharmaceutical and biotechnology companies in North America, while the fastest growth comes from software, from in-silico methods, from OMICS technologies, from organ toxicity endpoints, from pharmaceutical and biotechnology adoption, and from Asia-Pacific.
Customer perspectives
Head of Nonclinical Safety, Pharmaceutical Company, North America
Adoption runs ahead of regulatory reliance because an internal decision carries no submission risk, which is why platform vendors reach research budgets years before they reach regulated study budgets and why the gap between the two holds back conversion.
Toxicology Director, Cosmetics Company, Europe
The marketing ban applied to those endpoints regardless of whether alternatives existed, which left the cosmetics sector building and funding capability rather than purchasing established methods, and which is why it buys defended assessments rather than individual study results.
Study Director, Contract Research Organisation, Asia-Pacific
Mutual acceptance of data makes guideline compliance the condition of a study being usable in a global registration, which is why contract laboratories compete on exact guideline conformance rather than on method improvement and why guideline adoption rather than technique determines what they offer.
Frequently asked questions
The global in vitro toxicology and toxicity testing market is valued at USD 16.20 billion in 2026, up from USD 14.72 billion in 2025 and USD 13.38 billion in 2024.
Cite this report
Meticulous Research. (2026). In-Vitro Toxicology/Toxicity Testing Market - Global Opportunity Analysis and Industry Forecast (2019-2025) (Report No. MRHC - 104348). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/in-vitro-toxicology-toxicity-testing-market-5047